Pillstats
Rx only · Capsule, Extended Release

Dextroamphetamine Sulfate, Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, And Amphetamine Sulfate

Brands: Mydayis · Amphetamine Aspartate Monohydrate + Amphetamine Sulfate + Dextroamphetamine Saccharate + Dextroamphetamine Sulfate

2 ACTIVE SUPPLIERS — US
openFDA · updated weekly
US6 NDCs
2 active makers
UKComing
soon
CAComing
soon
AUComing
soon
EUComing
soon
RxCUI (US)3288
US makers2 labelers
Packages6
DEA / ScheduleCII

US acquisition costNADAC · per unit

Average across 4 priced NDCs. A benchmark of pharmacy acquisition cost — not a retail quote.

$3.11$6.21$9.32$12.43Dec 2025Apr 2026Jul 2026
$10.778
Latest avg · Jul 22, 2026
-0%
Since Dec 17, 2025
2
Active US suppliers
100%
Top-2 supplier share*

Medicaid dispensing volumeSDUD · per quarter

Prescriptions dispensed under Medicaid (fee-for-service + managed care), summed nationally. The closest free proxy to sales volume — Medicaid only, not all-payer.

1.8K3.6K5.4K7.2K2025 Q12025 Q22025 Q32025 Q42026 Q1
4.0K
Rx · 2026 Q1
118K
Units dispensed
-37%
Rx vs. year ago
5
Quarters · since 2025 Q1

Who makes it2 active · 0 exited

US labelers as registered with FDA. Repackagers relabel another company's product; share* is of listed packages, not sales.

LabelerTypePackagesStatus
Takeda Pharmaceuticals America, Inc.unknown4SUPPLYING
Patheon Inc.unknown2SUPPLYING

Regulatory & supply events

No recalls, shortages, or registration changes on record for this drug concept.